Capella

Capella—the Online Voice of Progress in RNAi

Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi into innovative medicines. For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we work to develop innovative medicines for patients.

Interim results from the open-label extension (OLE) period of the ENVISION Phase 3 study of GIVLAARI® (givosiran) in acute hepatic porphyria (AHP) were presented by study investigator Eliane Sardh, M.D., Ph.D. during a webinar hosted by Alnylam, demonstrating sustained efficacy and acceptable safety through 12 months of treatment, with evidence for potentially improved efficacy over time.

Read our press release

View the presentation

Webinar replay will be available here soon

(more…)

We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as clinical collaborators, will review recent progress in many of our pipeline programs and platform.

(more…)

The New England Journal of Medicine (NEJM) published pivotal results from the ENVISION Phase 3 study of givosiran, our RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria, in a manuscript titled “Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.”

Read our press release

Read the publication in the New England Journal of Medicine

(more…)

Positive results from the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic in development for the treatment of Primary Hyperoxaluria Type 1 (PH1), were presented by study investigators at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress, held June 6-9, 2020 as a virtual event.

Read the press release

View the presentation

(more…)

We presented new long-term results from the global Open-Label Extension (OLE) study of ONPATTRO® (patisiran) at the European Academy of Neurology (EAN) Virtual Congress, held May 23-26, 2020. In addition, results were presented from a Phase 3b trial evaluating treatment with patisiran in patients with hATTR amyloidosis with disease progression after receiving an orthotopic liver transplant (post-OLT). A post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran) was also presented.

Read the press release

View the patisiran global OLE poster

View the patisiran post-OLT poster

View the ENVISION post-hoc analysis

View the presentation on disease burden and healthcare utilization among patients with acute intermittent porphyria

(more…)

An abstract describing new 12-month interim data from the ongoing ENVISION open-label extension (OLE) study of givosiran in patients with acute hepatic porphyria (AHP) has been published online by the European Association for the Society of the Liver (EASL) on the International Liver Congress™ (ILC 2020) website.  The data will be presented during the ILC 2020 (London, UK) which was rescheduled to August 25-28, 2020 due to the COVID-19 pandemic.

View the ENVISION OLE abstract

(more…)

On November 22nd, 2019, we will be hosting an R&D Day in New York City. The event will showcase Alnylam’s late stage clinical efforts, next wave programs, and platform advances. The Company will also discuss its perspective on its transition toward achieving a self-sustainable financial profile.

To view the webcast, click here. A replay of the webcast will be available at that link on November 23rd.

To view the R&D Day Presentation, click here.

(more…)

We presented new positive efficacy results from the ongoing Phase 2 open-label extension (OLE) study of lumasiran, an investigational subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1), at the American Society of Nephrology (ASN) 2019 Annual Meeting, held November 5-10 in Washington, DC.

Read our press release

View the Phase 2 OLE poster

(more…)

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.